AKT1 and oral cavity squamous cell carcinoma: In silico studies introduced LN as inhibitors of Akt1 and Akt2 with strong binding affinities of 11.5 kcal/mol and 11.1 kcal/mol, respectively, with no affinity toward MAOB, which can be an ideal candidate for oral squamous cell carcinoma treatment [117].